Biologics

Synthetic completes acquisition of C. difficile infectious disease program

Tuesday, December 4, 2012 08:00 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for serious infections and diseases, has closed the previously announced deal with Prev AbR and acquired a series of beta-lactamase compounds (P1A, P2A and P3A) and related assets targeting the prevention of Clostridium difficile (C. diff) infection.

More... »

Synthetic Biologics raises $10.8M financing

Tuesday, October 30, 2012 12:48 PM

Synthetic Biologics, an Ann Arbor, Mich.-based biotech that develops of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing.

More... »

Premack joins Celtaxsys as chief technology officer

Friday, October 26, 2012 12:31 PM

Celtaxsys, a San Francisco-based, private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed life sciences technology expert, Brett A. Premack, Ph.D., as chief technology officer.

More... »

WuXi AppTec opens first cGMP biologics facility in China

Monday, October 22, 2012 11:11 AM

WuXi AppTec, a pharmaceutical, biotechnology and medical device R&D outsourcing company, has opened a cGMP biologics facility in China.

More... »

Synthetic Biologics, Intrexon collaborate on infectious diseases

Wednesday, August 8, 2012 01:55 PM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for unmet medical needs, and Intrexon, a Germantown, Md.-based synthetic biology company that provides control over cellular function, have entered into a second worldwide exclusive channel collaboration through which Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies.

More... »

DSM inks South American biologics contract manufacturing agreement

Monday, July 23, 2012 12:46 PM

DSM Pharmaceutical Products, a custom manufacturing and technology business of Royal DSM, has signed a biologics contract manufacturing agreement with its first Brazilian client, Recepta Biopharma, a Sao Paulo-based biotechnology company focused on monoclonal antibodies to treat cancer.

More... »

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

More... »

NIH awards Avaxia Biologics $1.5 million for bowel disease

Monday, March 19, 2012 10:57 AM

Avaxia Biologics, a privately-held biotech company based in Lexington, Mass., has received a second round of funding from the National Institutes of Health (NIH) to develop orally-active antibody therapeutics for the treatment of inflammatory bowel disease (IBD).

More... »

Avaxia raises $2.2 million in Series A financing

Friday, November 11, 2011 10:44 AM

Avaxia Biologics, a privately-held biotech company, has completed its first close of $2.2 million of a Series A angel-led financing. Cherrystone Angels of Providence, Rhode Island led the round, with participation from Boston Harbor Angels and other undisclosed individuals. Mr. Robert Manning, the co-Chairman of Cherrystone Angels, will join the Avaxia board.

More... »

Cobra Biologics acquires Unitech Pharma

Monday, October 31, 2011 10:49 AM

Cobra Biologics has acquired Unitech Pharma Group and its bio-production facility in Matfors near Sundsvall, Sweden.

More... »